Abstract 244P
Background
To evaluate the practical significance of the effectiveness of the modified coloring solution “CIN-DIAG” in the diagnosis of pathological changes of the cervix.
Methods
The modified CIN-DIAG coloring solution is a sterile cotton swab on a plastic stick in a plastic tube, and the coloring solution is in the cap of the tube. Appearance of the coloring solution: a clear brown liquid; The volume of the coloring solution is 2 ml ± 5%; the pH of the coloring solution is in the range of 4 to 7 units. Mechanism of action: after applying the staining solution to the epithelial tissue, in the presence of atypical cells, folic acid, via the folate receptors on the surface of these cells, quickly enters the cytoplasm, is oxidized by the active oxygen present in the cell, and the tampon stains at different intensities. Normal cells have a low content of active oxygen, so there is little expression of folic acid receptors on the surface of the cells and the tampon does not stain after the reaction.
Results
The study included 20 (100%) patients, of which: with CIN I - 5 (25%), CIN II - 3 (15%), CIN III - 4 (20%), patients with cervical cancer - 5 (25 %), with cervical erosion - 2 (10%) and 1 (5%) women with a visually unchanged cervix. The age of women ranged from 29 to 64 years, the average age was 40 ± 0.7 years (p>0,5). In case CIN1, the tampon was colored dark green, with CIN2 it was blue-green, with CIN3 it was blue, and with cervical cancer, it was dark gray and black. The results obtained fully met the requirements of the regulatory document, the sensitivity of the coloring solution was 98%, the specificity was 95%.
Conclusions
Thus, the modified CIN-DIAG coloring solution has the advantages of economy, affordability, low technical requirements, safety and non-invasiveness, as a result of which it can be successfully applied in remote regions of the country.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session